ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.97
0.00%
US Tech 100
20,235.20
0.54%
S&P 500
5,917.11
0.00%
US Dollar vs CAD
1.3962
-0.06%
Bitcoin
97,579.74
3.42%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kura Oncology Inc (KURA)

  7. Kura Oncology Inc (KURA) News

KURA

Kura Oncology (KURA)

Kura Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KURA
DateTimeSourceHeadlineSymbolCompany
11/20/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
11/20/20244:00PMPR Newswire (US)Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
11/20/20244:00PMGlobeNewswire Inc.Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
11/20/20244:00PMPR Newswire (US)Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
11/19/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
11/18/20243:03PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
11/07/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
11/07/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
11/07/20243:05PMGlobeNewswire Inc.Kura Oncology Reports Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
11/05/20248:09AMGlobeNewswire Inc.Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual MeetingNASDAQ:KURAKura Oncology Inc
10/31/20246:30AMGlobeNewswire Inc.Kura Oncology to Report Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
10/24/20246:30AMGlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
10/23/20246:30AMGlobeNewswire Inc.Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS InhibitorsNASDAQ:KURAKura Oncology Inc
09/30/20245:30PMGlobeNewswire Inc.Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet OncologyNASDAQ:KURAKura Oncology Inc
09/17/20243:10PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
09/17/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
09/17/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
09/17/20246:30AMGlobeNewswire Inc.Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of DirectorsNASDAQ:KURAKura Oncology Inc
09/10/20246:30AMGlobeNewswire Inc.Kura Oncology to Participate in Cantor Global Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
08/08/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
08/08/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
08/08/20243:05PMGlobeNewswire Inc.Kura Oncology Reports Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
08/08/20246:30AMGlobeNewswire Inc.Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
08/01/20246:30AMGlobeNewswire Inc.Kura Oncology to Report Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
07/05/20246:30AMGlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
06/24/20246:30AMGlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in DiabetesNASDAQ:KURAKura Oncology Inc
06/07/20243:30PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
06/07/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
06/07/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
06/07/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:KURA

Your Recent History

NASDAQ
NVDA
NVIDIA
NASDAQ
QUBT
Quantum Computing
USOTC
SINC
Sincerity Applied Materi... (PK)
COIN
BTCUSD
Bitcoin
USOTC
NSAV
Net Savings Link (PK)
USOTC
TGLO
TheGlobe com (PK)
USOTC
APRU
Apple Rush (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
MGON
Megola (PK)
USOTC
VDRM
ViaDerma (PK)
USOTC
AHRO
Authentic (PK)
NASDAQ
NB
NioCorp Developments
USOTC
BCAP
Baron Capital Enterprise (CE)
USOTC
ASII
Accredited Solutions (PK)
USOTC
RNVA
Rennova Health (CE)
USOTC
HHSE
Hannover House (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved